|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson’s disease显示文摘Parkinson’s disease is the second most common neurodegenerative disorder;it affects 1%of the population over the age of 65.The number of people with Parkinson’s disease is set to rapidly increase due to changing demographics and there is an unmet clinical need for disease-modifying therapies.The pathological hallmarks of Parkinson’s disease are the progressive degeneration of dopaminergic neurons in the substantia nigra and their axons which project to the striatum,and the aggregation ofα-synuclein;these result in a range of debilitating motor and non-motor symptoms.The application of neurotrophic factors to protect and potentially regenerate the remaining dopaminergic neurons is a major area of research interest.However,this strategy has had limited success to date.Clinical trials of two well-known neurotrophic factors,glial cell line-derived neurotrophic factor and neurturin,have reported limited efficacy in Parkinson’s disease patients,despite these factors showing potent neurotrophic actions in animal studies.There is therefore a need to identify other neurotrophic factors that can protect againstα-synuclein-induced degeneration of dopaminergic neurons.The bone morphogenetic protein(BMP)family is the largest subgroup of the transforming growth factor-βsuperfamily of proteins.BMPs are naturally secreted proteins that play crucial roles throughout the developing nervous system.Importantly,many BMPs have been shown to be potent neurotrophic factors for dopaminergic neurons.Here we discuss recent work showing that transcripts for the BMP receptors and BMP2 are co-expressed with several key markers of dopaminergic neurons in the human substantia nigra,and evidence for downregulation of BMP2 expression at distinct stages of Parkinson’s disease.We also discuss studies that explored the effects of BMP2 treatment,in in vitro and in vivo models of Parkinson’s disease.These studies found potent effects of BMP2 on dopaminergic neurites,which is important given that axon degeneration is increasingly recognized as a key early event in Parkinson’s disease.Thus,the aim of this mini-review is to give an overview of the BMP family and the BMP-Smad signalling pathway,in addition to reviewing the available evidence demonstrating the potential of BMP2 for Parkinson’s disease therapy. | Susan R.Goulding Aideen M.Sullivan Gerard W.O’Keeffe Louise M.Collins | 2020 | Neural Regeneration Research2020，15，8： | 7 |
| 2 | Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease显示文摘Neuroprotection and neuroregeneration are two of the most promising disease-modifying therapies for the incurable and widespread Parkinson's disease. In Parkinson's disease, progressive degeneration of nigrostriatal dopaminergic neurons causes debilitating motor symptoms. Neurotrophic factors play important regulatory roles in the development, survival and maintenance of specific neuronal populations. These factors have the potential to slow down, halt or reverse the loss of nigrostriatal dopaminergic neurons in Parkinson's disease. Several neurotrophic factors have been investigated in this regard. This review article discusses the neurodevelopmental roles and therapeutic potential of three dopaminergic neurotrophic factors: glial cell line-derived neurotrophic factor, neurturin and growth/differentiation factor 5. | Shane V.Hegarty Gerard W.O’Keeffe Aideen M.Sullivan | 2014 | Neural Regeneration Research2014，9，19： | 6 |
| 3 | A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update显示文摘 | Emmet B. Keeffe Douglas T. Dieterich Steven-Huy B. Han Ira M. Jacobson Paul Martin Eugene R. Schiff Hillel Tobias | 2008 | Clinical Gastroenterology and Hepatology2008，，12： | 5 |
| 4 | Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides显示文摘Nitazoxanide,the first thiazolide,was originally developed for the treatment of Cryptosporidium parvum.More recently,antiviral activity of nitazoxanide against hepatitis B virus(HBV)and hepatitis C virus was recognized in in vitro systems.These basic studies led to phaseⅡclinical trials that demonstrated the safety and efficacy of nitazoxanide in combination with peginterferon,with or without ribavirin,in the treatment of chronic hepatitis C genotype 4.The sustained virologic response rate was 79%and 80%in two studies,which was higher than the response rate of 50%with the standard of care with peginterferon plus ribavirin.In very preliminary studies of patients with chronic hepatitis B,nitazoxanide suppressed serum HBV DNA and led to loss of hepatitis B e antigen in the majority of patients and hepatitis B surface antigen in approximately a quarter of patients.Randomized controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 are underway,new second generation and controlled release thiazolides are being developed,and future studies of patients with chronic hepatitis B are planned. | Emmet B Keeffe Jean-Franois Rossignol | 2009 | World Journal of Gastroenterology2009，15，15： | 5 |
| 5 | A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update显示文摘 | Emmet B. Keeffe Douglas T. Dieterich Steven–Huy B. Han Ira M. Jacobson Paul Martin Eugene R. Schiff Hillel Tobias Teresa L. Wright | 2006 | Clinical Gastroenterology and Hepatology2006，，8： | 2 |
| 6 | Chronic hepatitis B:preventing,detecting,and managing viral resistance显示文摘 | Keeffe EB Dieterich DT Pawlotsky JM | | 0，，： | 2 |
| 7 | Ultrasound elastography as an adjuvant to conventional ultrasound in the preoperative assessment of axillary lymph nodes in suspected breast cancer: A pilot study显示文摘 | K. Taylor S. O’Keeffe P.D. Britton M.G. Wallis G.M. Treece J. Housden D. Parashar S. Bond R. Sinnatamby | 2011 | Clinical Radiology2011，，11： | 2 |
| 8 | Neurotrophic factor therapy for Parkinson's disease: past, present and future显示文摘One of the greatest unmet needs in the treatment of Parkinson’s disease(PD)is a disease-modifying therapy,which can halt the ongoing degeneration of dopaminergic neurons that is characteristic of this disorder.Current therapies focus on managing symptoms,rather than on addressing their cause.Promising candidates for disease-modifying therapies are the dopaminergic neurotrophic factors(NTFs).NTFs are | Aideen M.Sullivan Gerard W.O'Keeffe | 2016 | Neural Regeneration Research2016，11，2： | 2 |
| 9 | Racial differences in effectiveness of α-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis显示文摘 | Mindie H Nguyen Ruel T Garcia Peter W Simpson Teresa L Wright Emmet B Keeffe | 2002 | Hepatology2002，，2： | 2 |
| 10 | Flupoxam——一种防除越冬谷物田中芽前、芽后阔叶杂草的除草剂显示文摘Flupoxam系日本吴羽化学公司发现(代号:KNW-739),并与孟山都公司共同开发的一种新型除草剂(代号:Mon18500),可用于防除越冬谷物田中芽前、芽后的一年生阔叶杂草。 | H.G.O'Keeffe T.Chida 彭玉宁 | 1992 | 农药译丛1992，14，4： | 2 |
| 11 | Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B显示文摘 | Keeffe EB Zeuzem S Koff RS | | Clinical Gastroenterology and Hepatology0，，： | 2 |
| 12 | Reticular chemistry:occurrence and taxonomy of nets and grammar for the design of frameworks显示文摘 | Ockwig N W Delgado-Friedrichs O O'Keeffe M | 2005 | Acc Chem Res2005，38，： | 1 |
| 13 | Synthesis and Structure Refinement of the Spinel,γ-Ge3N4显示文摘 | Leinenweber K O'Keeffe M Somayazulu M | 1999 | Chem Eur J1999，5，： | 1 |
| 14 | Hepatitis B vaccines显示文摘 | Yu AS Cheung RC Keeffe EB | 2004 | Clin Liver Dis2004，8，2： | 1 |
| 15 | Donor age affects differentiation of rat ventral mesencephalic stem cells显示文摘 | O'Keeffe G W Sullivan A M | 2005 | Neurosci Lett2005，375，2： | 1 |
| 16 | A treatment algorithm for the man- agement of chronic hepatitis B virus infection in the United States: an update 显示文摘 | Keeffe EB Dieterich DT Han SH | 2006 | Clin Gastroenterol Hepatul2006，4，8： | 1 |
| 17 | Design and synthesis of an exceptionally stable and highly porous metal-organic framework显示文摘 | Li H Eddaoudi M O' Keeffe M | 1999 | Nature1999，402，： | 1 |
| 18 | Systematic design of pore size and functionality in isoreticular MOFs and their application in methane storage显示文摘 | Eddaoudi Mohamed Kim Jaheon Rosi Nathaniel Vodak David Wachter Joseph O'Keeffe Michael Yaghi Omar M | 2002 | Science2002，295，： | 1 |
| 19 | Large-pore apertures in a series of metal-organic frameworks显示文摘 | Deng H Grunder S Cordova K E Valente C Furukawa H Hmadeh M Gandara F Whalley A C Liu Z Asahina S Kazumori H O'Keeffe M Terasaki O Stoddart J F Yaghi O M | 2012 | Science2012，336，： | 1 |
| 20 | Reticular synthesis and the design of new materials显示文摘 | O'KEEFFE M EDDAOUDI M LI H | 2000 | J Solid State Chem2000，3，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员